Guía de atención integral para la detección oportuna, diagnóstico, tratamiento y seguimiento de leucemia linfoide aguda en niños, niñas y adolescentes

Autores/as

  • Martha Vizcaíno Centro Javeriano de Oncología
  • John Edgar Lopera Instituto Nacional de Cancerología
  • Leila Martínez Clínica Colsubsidio
  • Iliana De los Reyes Centro Javeriano de Oncología
  • Adriana Linares Universidad Nacional de Colombia

Palabras clave:

Guía de práctica clínica, Garantía de la calidad de atención de salud, Leucemia linfoide aguda, Niños, Pediatría, Colombia

Resumen

La leucemia linfoide aguda (LLA) es el cáncer más frecuente en niños. A nivel mundial se estima que cerca del 30% corresponde a la totalidad de las neoplasias malignas que se presentan en niños y, de estas, más del 75% son LLA.
En Colombia no existe aún un registro nacional de cáncer que nos permita evaluar exactamente la carga de la enfermedad por esta patología; sin embargo, se estima que se presentan aproximadamente 2.080 casos nuevos por año de cáncer en pacientes pediátricos y de estos 500 corresponden a LLA. Con el objetivo de disminuir la mortalidad y mejorar la oportunidad en el diagnóstico y en el tratamiento de los niños afectados por esta patología, se desarrolló esta Guía de práctica clínica (GPC) como producto del trabajo durante meses de un grupo organizado y motivado de médicos especialistas en el área (epidemiólogos, economistas, entre otros), quienes elaboraron recomendaciones para las diferentes etapas tanto para la prevención, sospecha, diagnóstico, tratamiento, seguimiento de los niños y adolescentes con diagnóstico de LLA.

Biografía del autor/a

Martha Vizcaíno, Centro Javeriano de Oncología

Grupo de Pediatría, Centro Javeriano de Oncología, Bogotá D.C., Colombia

John Edgar Lopera, Instituto Nacional de Cancerología

Grupo de Pediatría, Instituto Nacional de Cancerología, Bogotá D.C., Colombia

Leila Martínez, Clínica Colsubsidio

Grupo de Pediatría, Clínica Colsubsidio, Bogotá D.C., Colombia

Iliana De los Reyes, Centro Javeriano de Oncología

Grupo de Pediatría, Centro Javeriano de Oncología, Bogotá D.C., Colombia

Adriana Linares, Universidad Nacional de Colombia

Grupo de Pediatría, Universidad Nacional de Colombia, Bogotá D.C., Colombia

Referencias bibliográficas

Pombo-de-Olivera MS, Koifman S, Brazilian Collaborative Study Group of Infant Acute Leukemia. Infant acute leukemia and maternal exposures during pregnancy. Cancer Epidemiol Biomarkers Prev. 2006;15(12):2336-41.

https://doi.org/10.1158/1055-9965.EPI-06-0031

Piñeros M, Pardo C, Otero J, Suárez A, Vizcaíno M, Álvarez V, et al. Guidelines for Epidemiologic Surveillance of Acute Pediatric Leukemias in Colombia. Rev Colomb Cancerol. 2007;11(4):219-27.

Wigle DT, Turner MC, Krewski D. A systematic review and meta-analysis of childhood leukemia and parental occupational pesticide exposure. Environ Health Perspect. 2009;117(10): 1505-13.

https://doi.org/10.1289/ehp.0900582

Rull RP, Gunier R, Von Behren J, Hertz A, Crouse V, Buffler PA, et al. Residential proximity to agricultural pesticide applications and childhood acute lymphoblastic leukemia. Environ Res. 2009;109(7):891-9.

https://doi.org/10.1016/j.envres.2009.07.014

Caughey RW, Michels KB. Birth weight and childhood leukemia: a meta-analysis and review of the current evidence. Int J Cancer. 2009;124(11):2658-70.

https://doi.org/10.1002/ijc.24225

Hjalgrim LL, Westergaard T, Rostgaard K, Schmiegelow K, Melbye M, Hjalgrim H, et al. Birth Weight as a risk factor for childhood leukemia: a meta-analysis of 18 epidemiologic studies. Am J Epidemiol. 2003;158(8):724-35.

https://doi.org/10.1093/aje/kwg210

Ripert M, Menegaux F, Perel Y, Méchinaud F, Gandemer V, Lutz P, et al. Familial history of cancer and childhood acute leukemia: a French population-based case-control study. Eur J Cancer Prev. 2007;16(5):466-70.

https://doi.org/10.1097/01.cej.0000243849.82232.cb

Organización Mundial de la Salud. Organizacio'n Panamericana de la Salud. Manual de atencio'n integrada a las enfermedades prevalentes de la infancia. Washington, D.C.: Organizacio'n Panamericana de la Salud; 2011.

van Tilburg CM, Sanders EA, Nibbelke EE, Pieters R, Revesz T, Westers P, et al. Impact of reduced chemotherapy treatment for good risk childhood acute lymphoblastic leukaemia on infectious morbidity. Br J Haematol. 2011;152(4):433-40.

https://doi.org/10.1111/j.1365-2141.2010.08463.x

Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol. 2014;32(3):174-84.

https://doi.org/10.1200/JCO.2013.48.6522

Neale GA, Coustan-Smith E, Stow P, Pan Q, Chen X, Pui CH, et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 2004;18(5):934-8.

https://doi.org/10.1038/sj.leu.2403348

Ryan J, Quinn F, Meunier A, Boublikova L, Crampe M, Tewari P, et al. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches. Br J Haematol. 2009;144(1):107-15.

https://doi.org/10.1111/j.1365-2141.2008.07429.x

Conter V, Aricò M, Basso G, Biondi A, Barisone E, Messina C, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):255-64.

https://doi.org/10.1038/leu.2009.250

Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-78.

https://doi.org/10.1056/NEJMra052603

Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007;109(3):926-35.

https://doi.org/10.1182/blood-2006-01-024729

Pui CH, Pei D, Campana D, Bowman WP, Sandlund JT, Kate SC, et al. Improved prognosis of older adolescents with acute lymphoblastic leukemia. J Clin Oncol. 2011;29(4):386-91.

https://doi.org/10.1200/JCO.2010.32.0325

Ribera JM, Oriol A, Sanz MA, Tormo M, Fernández-Abellán P, del Potro E, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espa˜nol de Tratamiento en Hematología pediatric-based protocol ALL-96. J Clin Oncol. 2008;26(11):1843-9.

https://doi.org/10.1200/JCO.2007.13.7265

Nachman JB, Heerema NA, Sather H, Camitta B, Forestier E, Harrison CJ, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood. 2007;110(4):1112-5.

https://doi.org/10.1182/blood-2006-07-038299

Karachunskiy A, Herold R, von Stackelberg A, Miakova N, Timakow A, Mahortih T, et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemi in Russia. Leukemia. 2008;22(6):1144-53.

https://doi.org/10.1038/leu.2008.63

Pui CH. Treatment of Childhood Acute Lymphoblastic Leukemia Whitout Phrophylactic Cranial Irradiation. N Engl J Med. 2009;354:166-78.

https://doi.org/10.1056/NEJMra052603

Escherich G, Horstmann MA, Zimmermann M, Janka-Schaub GE, COALL study group. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97. Leukemia. 2010;24(2):298-308.

https://doi.org/10.1038/leu.2009.249

Eden T, Pieters R, Richards S, Childhood Acute Lymphoblastic Leukemia Collaborative Group (CALLCG). Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5659 children. Br J Haematol. 2010;149(5):722-33.

https://doi.org/10.1111/j.1365-2141.2010.08148.x

Schwartz CL, Thompson EB, Gelber RD, Young ML, Chilton D, Cohen HJ, et al. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol. 2001;19(4):1040-6.

https://doi.org/10.1200/JCO.2001.19.4.1040

Kamps WA, Bökkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, van Wering ER, et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia. 2002;16(6):1099-111.

https://doi.org/10.1038/sj.leu.2402489

Chauvenet AR, Martin PL, Devidas M, Linda SB, Bell BA, Kurtzberg J, et al. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood. 2007;110(4): 1105-11.

https://doi.org/10.1182/blood-2006-12-061689

Vilmer E, Suciu S, Ferster A, Bertrand Y, Cavé H, Thyss A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia. 2000;14(12):2257-66.

https://doi.org/10.1038/sj.leu.2401960

Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P, et al. Comparison of Escherichia coli---asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood. 2002;99(8):2734-9.

https://doi.org/10.1182/blood.V99.8.2734

Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dordelmann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111(9):4477-89.

https://doi.org/10.1182/blood-2007-09-112920

Aricò M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010;28(31):4755-61.

https://doi.org/10.1200/JCO.2010.30.1325

Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. 2010;28(14):2339-47.

https://doi.org/10.1200/JCO.2009.25.1983

Chessells JM, Harrison G, Richards SM, Gibson BE, Bailey CC, Hill FG, et al. Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI. Br J Haematol. 2002;118(2):445-55.

https://doi.org/10.1046/j.1365-2141.2002.03647.x

Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood. 2011;118(4):874-83.

https://doi.org/10.1182/blood-2010-06-292615

Nathan PC, Whitcomb T, Wolters PL, Steinberg SM, Balis FM, Brouwers P, et al. Very high-dose methotrexate (33.6 g/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/ Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P. Leuk Lymphoma. 2006;47(12):2488-504.

https://doi.org/10.1080/10428190600942769

Schmiegelow K, Björk O, Glomstein A, Gustafsson G, Keiding N, Kristinsson J, et al. Intensification of mercaptopurine/ methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol. 2003;21(7):1332-9.

https://doi.org/10.1200/JCO.2003.04.039

Clarke M, Gaynon P, Hann I, Harrison G, Masera G, Peto R, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol. 2003;21(9):1798-809.

https://doi.org/10.1200/JCO.2003.08.047

Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, et al., German-Austrian-Swiss ALL-BFM Study Group. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood. 2000;95(11):3310-22.

Tsuchida M, Ohara A, Manabe A, Kumagai M, Shimada H, Kikuchi A, et al. Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984- 1999. Leukemia. 2010;24(2):383-96.

https://doi.org/10.1038/leu.2009.260

Sasse EC, Sasse AD, Brandalise S, Clark OA, Richards S. Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia. Cochrane Database Syst Rev. 2005;20(3):CD004139.

https://doi.org/10.1002/14651858.CD004139.pub2

Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11(10): 950-61.

https://doi.org/10.1016/S1470-2045(10)70204-7

Scrideli CA, Assumpc¸ão JG, Ganazza MA, Araújo M, Toledo SR, Lee ML, et al. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups. Haematologica. 2009;94: 781-9.

https://doi.org/10.3324/haematol.2008.003137

Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206-14.

https://doi.org/10.1182/blood-2009-10-248146

Langerbrake C, Reinhardt D, Ritter J. Minimizing the long-term adverse effects of childhood leukemia therapy. Drug safety. 2002;25(15):1057-77.

https://doi.org/10.2165/00002018-200225150-00002

Leung W, Hudson M, Zhu Y, Rivera GK, Ribeiro RC, Sandlund JT, et al. Late effects in survivors of infant leukemia. Leukemia. 2000;14(7):1185-90.

https://doi.org/10.1038/sj.leu.2401818

Cómo citar

[1]
Vizcaíno, M., Lopera, J.E., Martínez, L., De los Reyes, I. y Linares, A. 2016. Guía de atención integral para la detección oportuna, diagnóstico, tratamiento y seguimiento de leucemia linfoide aguda en niños, niñas y adolescentes. Revista Colombiana de Cancerología. 20, 1 (mar. 2016), 17–27.

Descargas

Los datos de descargas todavía no están disponibles.

Descargas

Publicado

2016-03-01

Número

Sección

Artículos especiales